GlyProVac Overview
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
2ndary - Private
- Investors
-
9
GlyProVac General Information
Description
Developer of a glycoprotein-based vaccine designed for the treatment of enterotoxigenic escherichia coli. The company's BEMAP technology allows comprehensive identification of any type of O-linked protein glycosylation that acts as a reservoir of attractive targets for antimicrobial intervention, enabling people to strengthen their immune systems thus preventing the infection caused by the enterotoxigenic escherichia coli bacterium.
Contact Information
Website
www.glyprovac.comCorporate Office
- Rørhatten 4
- 5220 Odense
- Denmark
Corporate Office
- Rørhatten 4
- 5220 Odense
- Denmark
GlyProVac Timeline
GlyProVac Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Secondary Transaction - Private | 03-Mar-2026 | Completed | Generating Revenue | |||
| 10. Grant | 01-Jan-2024 | Completed | Generating Revenue | |||
| 9. Later Stage VC | 28-Sep-2023 | Completed | Generating Revenue | |||
| 8. Seed Round | 30-Jun-2021 | Completed | Generating Revenue | |||
| 7. Seed Round | 07-Dec-2020 | Completed | Generating Revenue | |||
| 6. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 5. Angel (individual) | 01-Jan-2018 | Completed | Generating Revenue | |||
| 4. Grant | Completed | Generating Revenue | ||||
| 3. Grant | $156K | Completed | Generating Revenue | |||
| 2. Grant | 01-Jan-2014 | $368K | Completed | Generating Revenue |
GlyProVac Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 3,742 | $25.1 | $25.1 | 1x | $25.1 | 2.73% | ||
| Ordinary | 18,655 | $17.23 | $17.23 | 1x | $17.23 | 13.63% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
GlyProVac Patents
GlyProVac Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025219177-A1 | Optimized plasmids for expression of yghj polypeptides | Pending | 18-Apr-2024 | ||
| AU-2023362022-A1 | Glycosylated yghj polypeptides from uropathogenic e. coli | Pending | 19-Oct-2022 | ||
| EP-4605414-A1 | Glycosylated yghj polypeptides from uropathogenic e. coli | Pending | 19-Oct-2022 | ||
| US-20260285915-A1 | Glycosylated yghj polypeptides from uropathogenic e. coli | Pending | 19-Oct-2022 | ||
| WO-2024083912-A1 | Glycosylated yghj polypeptides from uropathogenic e. coli | Inactive | 19-Oct-2022 | A61P31/04 |
GlyProVac Signals
GlyProVac Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CARB-X | University | |||
| Angel (individual) | Minority | |||
| Angel (individual) | Minority | |||
| Angel (individual) | Minority | |||
| Syddansk Innovation | Venture Capital | Minority |
GlyProVac FAQs
-
Where is GlyProVac headquartered?
GlyProVac is headquartered in Odense, Denmark.
-
What is the size of GlyProVac?
GlyProVac has 4 total employees.
-
What industry is GlyProVac in?
GlyProVac’s primary industry is Drug Discovery.
-
Is GlyProVac a private or public company?
GlyProVac is a Private company.
-
What is GlyProVac’s current revenue?
The current revenue for GlyProVac is .
-
How much funding has GlyProVac raised over time?
GlyProVac has raised $2.15M.
-
Who are GlyProVac’s investors?
CARB-X, , , , and Syddansk Innovation are 5 of 9 investors who have invested in GlyProVac.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process